WCP
BMRN icon

Wick Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wick Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Sell
3,687
-892
-19% -$48.9K 0.03% 232
2026
Q1 		$259K Buy
4,579
+266
+6% +$15.5K 0.05% 179
2025
Q4 		$256K Buy
+4,313
New +$235K 0.05% 167

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Wick Capital Partners's BMRN Position: Q2 2026 in Review

Wick Capital Partners reduced its BioMarin Pharmaceuticals (BMRN) stake by 19% in Q2 2026, selling an estimated $48.9K and leaving 3,687 shares worth $211K. The position accounts for 0.03% of the portfolio, ranked #232.

Wick Capital Partners first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $259K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Wick Capital Partners held 3,687 shares of BioMarin Pharmaceuticals worth $211K as of Q2 2026.
  • Wick Capital Partners sold 892 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $48.9K.
  • BioMarin Pharmaceuticals made up 0.03% of Wick Capital Partners's portfolio in Q2 2026, its #232 holding.
  • Wick Capital Partners first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Wick Capital Partners's BioMarin Pharmaceuticals position peaked at $259K in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Wick Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.